Will FedEx’s Spinoff Boost Its Stock Price?
In a pre-holiday surprise announcement, management at FedEx (NYSE:FDX) released…
Sell
49
DCTH Quote, Financials, Valuation and Earnings
Last price:
$11.93
Seasonality move
:
-5.88%
Day range:
$11.42 - $12.00
52-week range:
$3.70 - $13.30
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
14.33x
P/B ratio:
44.62x
Volume:
268.7K
Avg. volume:
385.1K
1-year change:
194.58%
Market cap:
$382.4M
Revenue:
$2.1M
EPS (TTM):
-$1.20
Analysts' Opinion
-
Consensus RatingDelcath Systems has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Delcath Systems has an estimated upside of 78.37% from its current price of $11.96.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $11.96.
Fair Value
-
According to the consensus of 0 analysts, Delcath Systems has 78.37% upside to fair value with a price target of -- per share.
DCTH vs. S&P 500
-
Over the past 5 trading days, Delcath Systems has overperformed the S&P 500 by 6.26% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Delcath Systems does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Delcath Systems has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Delcath Systems reported revenues of $11.2M.
Earnings Growth
-
Delcath Systems has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Delcath Systems reported earnings per share of $0.06.
Enterprise value:
370.4M
EV / Invested capital:
35.04x
Price / LTM sales:
14.33x
EV / EBIT:
--
EV / Revenue:
16.36x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-14.14x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$18.4M
Return On Assets:
-90.81%
Net Income Margin (TTM):
-150.7%
Return On Equity:
-251.36%
Return On Invested Capital:
-167.55%
Operating Margin:
-11.24%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $4.2M | $2.2M | $22.6M | $434K | $11.2M | |
| Gross Profit | $3.6M | $1.5M | $18.4M | $301K | $9.6M | |
| Operating Income | -$30.7M | -$34.7M | -$26.8M | -$10.6M | -$1.3M | |
| EBITDA | -$30.5M | -$42.5M | -$36.8M | -$19.7M | -$1.2M | |
| Diluted EPS | -$3.99 | -$3.33 | -$1.20 | -$1.14 | $0.06 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $13.9M | $32.3M | $18.5M | $46.1M | $28.9M | |
| Total Assets | $16.6M | $34.4M | $20.2M | $47.6M | $31.7M | |
| Current Liabilities | $10.6M | $5.4M | $14.4M | $14M | $21.6M | |
| Total Liabilities | $13.3M | $22.7M | $25.5M | $22.9M | $23.1M | |
| Total Equity | $3.3M | $11.7M | -$5.2M | $24.7M | $8.6M | |
| Total Debt | $2M | $15.4M | $16.2M | $10M | $2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$23.6M | -$30.4M | -$25.9M | -$9.2M | -$3.6M | |
| Cash From Investing | -$208K | -$39K | -$5.4M | $1K | -$697K | |
| Cash From Financing | $8.8M | $57M | -$974K | $35.1M | -$2.1M | |
| Free Cash Flow | -$23.8M | -$30.5M | -$26.2M | -$9.2M | -$3.9M | |
DCTH
Sector
Market Cap
$382.4M
$45.9M
Price % of 52-Week High
89.92%
46.95%
Dividend Yield
0%
0%
Shareholder Yield
-2.11%
-0.6%
1-Year Price Total Return
194.58%
-32.15%
Beta (5-Year)
0.851
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$11.48
200-day SMA
Buy
Level
$8.24
Bollinger Bands (100)
Buy
Level
8.55 - 11.29
Chaikin Money Flow
Sell
Level
-1.3B
20-day SMA
Buy
Level
$11.73
Relative Strength Index (RSI14)
Buy
Level
57.14
ADX Line
Buy
Level
17.94
Williams %R
Neutral
Level
-52.5695
50-day SMA
Buy
Level
$10.93
MACD (12, 26)
Buy
Level
0.25
25-day Aroon Oscillator
Buy
Level
60
On Balance Volume
Sell
Level
-202M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-19.0825)
Sell
CA Score
(Annual)
Level (-9.3084)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (9.5053)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Stock Forecast FAQ
In the current month, DCTH has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The DCTH average analyst price target in the past 3 months is --.
-
Where Will Delcath Systems Stock Be In 1 Year?
According to analysts, the consensus estimate is that Delcath Systems share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Delcath Systems?
Analysts are divided on their view about Delcath Systems share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Delcath Systems is a Sell and believe this share price will drop from its current level to --.
-
What Is Delcath Systems's Price Target?
The price target for Delcath Systems over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is DCTH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Delcath Systems is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of DCTH?
You can purchase shares of Delcath Systems via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Delcath Systems shares.
-
What Is The Delcath Systems Share Price Today?
Delcath Systems was last trading at $11.93 per share. This represents the most recent stock quote for Delcath Systems. Yesterday, Delcath Systems closed at $11.96 per share.
-
How To Buy Delcath Systems Stock Online?
In order to purchase Delcath Systems stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Buffett Buying Verisign?
Warren Buffett has spent 2024 stockpiling cash, even going so…
Is Microsoft an Undervalued Growth Stock to Buy?
Tech giant Microsoft (NASDAQ:MSFT) has been one of the biggest…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
54
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
LMND alert for Dec 30
Lemonade [LMND] is down 2.82% over the past day.
Buy
63
SMLR alert for Dec 30
Semler Scientific [SMLR] is down 11.17% over the past day.
Sell
39
DOGZ alert for Dec 30
Dogness (International) [DOGZ] is up 3.61% over the past day.
